PF-07934040 + fluorouracil + oxaliplatin + leucovorin + bevacizumab

**PF-07934040 + fluorouracil + oxaliplatin + leucovorin + bevacizumab** is an investigational combination therapy being evaluated in clinical trials for the treatment of advanced solid tumors that harbor KRAS gene mutations, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC)[2][3][5]. - **PF-07934040** is a small molecule, orally administered pan-KRAS inhibitor targeting multiple KRAS mutations (e.g., G12C, G12D, G12V, G12R, G12S, G13D, Q61H)[1][4][5]. It inhibits KRAS signaling, which is frequently dysregulated in various cancers, leading to uncontrolled cell growth and tumor progression[1][4]. - **Fluorouracil** is a pyrimidine analog used as a chemotherapeutic antimetabolite to disrupt DNA synthesis[5]. - **Oxaliplatin** is a platinum-based cytotoxic agent causing DNA crosslinking and apoptosis[5]. - **Leucovorin** (folinic acid) enhances the therapeutic effects of fluorouracil by stabilizing binding to thymidylate synthase[5]. - **Bevacizumab** is a recombinant monoclonal antibody that selectively binds to and inhibits Vascular Endothelial Growth Factor A (VEGF-A), blocking angiogenesis involved in tumor growth and metastasis[5]. This combination is delivered as oral PF-07934040 (tablet) plus intravenous administration of the chemotherapy agents and monoclonal antibody as per standard regimens (e.g., FOLFOX plus bevacizumab)[3][5].